Entera Bio Ltd. (ENTX) is a pre-revenue clinical-stage Israeli biotech with zero tangible operating assets of consequence. Under a liquidation lens as of March 31, 2026, the recovery posture is marginally positive but structurally fragile and trending negative. Total assets are $13.1 million against total liabilities of $2.4 million, yielding reported book equity of $10.7 million. Applying liquidation haircuts: cash and cash equivalents of $4.1 million recover at par; restricted cash of $7.9 million (of which $7.8 million is contractually designated to fund OPKO collaboration obligations under the A&R Collaboration Agreement) is nominally recoverable at par but is effectively encumbered — a liquidating entity would face immediate dispute over whether those funds revert to general creditors or must be returned to OPKO. PP&E of $0.1 million at 50-70% yields $50-90k. The operating lease ROU asset of $0.4 million receives zero recovery. Intangibles and IP platform carry zero liquidation value. Other current assets of $0.6 million (prepaid expenses, collaboration receivable) recover at 60-80% or less. On the liability side: current liabilities of $1.6 million and non-current liabilities of $0.9 million stand at face value, with operating lease obligations ($0.4 million combined current and non-current) not extinguishing on windup. The non-current 'other long-term debt' of $0.6 million (collaboration deferred liability under ASC 808) would need to be settled or refunded at face. Net recovery to equity, excluding the encumbered restricted cash, is negative. Including restricted cash at par, nominal recovery is approximately $10-11 million, but that figure is misleading given the OPKO designation. Accumulated deficit stands at $128.9 million. Operating cash burn was $3.1 million for Q1 2026, accelerating from $1.4 million in Q1 2025, driven by EB613 Phase 3 preparation costs and new OPKO collaboration expenses ($0.5 million net OPKO cost in Q1 2026 vs. zero in Q1 2025). Management has issued a going concern qualification, stating cash resources (including the April 2026 $10 million private placement) are sufficient only through Q1 2027. The April 2026 private placement with BVF Partners LP ($10 million gross, closed post-period) would improve the liquidity position but is not reflected in the March 31, 2026 balance sheet. The filing does not separately XBRL-tag the collaboration deferred liability or the restricted cash encumbrance attributable to OPKO — these are disclosed only in MD&A and footnotes.
▼ Community Notes